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in the intestine, liver and skin on day 60. All of BMT recipients
showed complete donor engraftment. Examination of T cells in the
spleen on day 14 showed that CD100 / T cells expanded
fourfold less than wild type (P  .01). Together our data show that
Sema4D is a co-stimulatory molecule that modulates T cell allo-
geneic responses both in vitro and in vivo and may represent a
novel target for the prevention of GvHD (Table 1).
Table 1. CD100/ vs Wild Type T Cell Transplant Outcomes
Day post
Transplant
wt T
Cells n
CD100/
T Cells n
P
Value
GvHD clinical
score
60 4.6  0.8 6 1.8  0.2 6 <.02
Survival 60 67% 6 100% 6 .08
Liver pathology 60 17.0  1.5 4 9.0  1.3 4 <.01
Skin pathology 60 1.5  0.2 4 0.8  0.2 4 .02
Intestinal
pathology
60 7.8  0.8 8 4.8  1.0 8 .03
T cell expansion
(106)
14 3.95  0.78 5 0.83  0.16 5 <.01
95% conﬁdence interval.
167
EXTRACORPOREAL PHOTOPHERESIS (ECP) STIMULATES THE GENER-
ATION OF REGULATORY T CELLS
Strobl, F.J., Huber, J., Krutsick, A., Campbell, K.A., Peritt, D.
THERAKOS, Inc., Exton, PA.
Extracorporeal photopheresis (ECP) involves the reinfusion of
autologous, apoptotic peripheral blood leukocytes treated ex vivo
with 8-methoxypsoralen (8-MOP) and UVA light. ECP is ap-
proved for the palliative treatment of cutaneous T cell lymphoma.
ECP has also shown promise as a treatment for other immune-
mediated inﬂammatory disorders suggesting a common immuno-
logic pathway may be involved in it’s mechanism of action. Several
investigators including ourselves have recently provided in vivo
evidence to suggest that the delivery of ECP-treated apoptotic cells
modulates immune responses, in part, through the generation of
regulatory T cells. In vitro studies have also demonstrated that
activation of naive T cells in the presence of antigen presenting
cells (APCs) that have previously engulfed ECP-treated apoptotic
cells leads to the generation of a T cell population that can suppress
syngeneic T cell proliferation and function. In this study, we
expand the scope of these original ﬁndings by demonstrating that
co-incubation of naive CD4 T cells with ECP-treated peripheral
blood mononuclear cells also results in the development of a
regulatory T cell phenotype. ECP-mediated generation of regula-
tory T cells is dependent on APCs and can be reversed by the
addition of interleukin-2 (IL-2). These regulatory T cells actively
proliferate in response to concanavalin-A (Con A) but do not
secrete signiﬁcant levels of pro-inﬂammatory cytokines. Transfer
of these regulatory T cells to a secondary MLR reaction results in
the inhibition of syngeneic responder T cell proliferation. Addi-
tional studies are underway to characterize these cells and deter-
mine their suppressive capacity in vivo. Collectively, these results
demonstrate that ECP-treated apoptotic cells are capable of mod-
ulating other immune cells, in part, through the generation of
regulatory T cells. Regulatory T cells have been implicated in the
control of a variety of immune-mediated inﬂammatory diseases. It
is hoped that a better understanding of the mechanism of action
behind ECP will help to deﬁne more efﬁcacious and cost-effective
treatment regimens.
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ROLE FOR ACTIVATED DONOR NK CELLS IN PROTECTION FROM
ACUTE, LETHAL GVHD AND THE PROMOTION OF ENGRAFTMENT IN A
PARENTAL STRAIN3F1-HYBRID MODEL
Ellison, C.A.1,2, Fischer, J.M.M.1, Gartner, J.G.1,3 1. Department of
Pathology, University of Manitoba, Winnipeg, MB, Canada; 2. Mani-
toba Blood and Marrow Transplant Program, CancerCare Manitoba,
Winnipeg, MB, Canada; 3. Department of Immunology, University of
Manitoba, Winnipeg, MB, Canada.
The effects of donor NK cells in allogeneic bone marrow trans-
plantation and the development of GVHD remains controversial.
Using the C57BL/63(C57BL/6  DBA/2)F1-hybrid model of
acute GVHD, we performed experiments in which the donor mice
were stimulated with polyinosinic:polycytidylic acid (poly I:C) be-
fore the grafts were harvested. Poly I:C is a potent activator of NK
cell cytotoxicity and an inducer of interferon production. In some
of these experiments, we also removed the adherent cells from the
graft prior to transplantation. The following four experimental
groups were established: (1) recipients of unmanipulated grafts
from unstimulated donors; (2) recipients of unmanipulated grafts
from poly I:C-stimulated donors; (3) recipients of non-adherent
grafts from unstimulated donors; and (4) recipients of non-adher-
ent grafts from poly I:C-stimulated donors. The only group in
which protection from acute, lethal GVHD was seen was group
(4), in which 75% of the recipients survived until at least day 90
post-induction. Only 50% of the recipients in group (4) survived
when the graft was depleted of DX5 cells using a magnetic cell
sorter. This was also associated with a marked reduction in the
level of engraftment of total donor cells, as well as donor T cells in
the long-term survivors in group (4). Our ﬁndings show that
recipients of grafts from poly I:C-stimulated donors are only pro-
tected when the adherent cells are removed from the graft but the
precise mechanism through which protection is achieved is not
known. They further show that donor DX5 cells are at least partly
responsible for the protection we observed and that these cells
promote engraftment, particularly of T cells. Supported by an
establishment grant to CAE from the CancerCare Manitoba Foun-
dation.
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SKIN EXPLANT MODEL OF HUMAN GVHD: PREDICTION OF CLINICAL
OUTCOME AND CORRELATION WITH BIOLOGICAL RISK FACTORS
Wang, X.-N.1, Collin, M.1, Sviland, L.2, Marshall, S.R.1,
Jackson, G.H.3, Schulz, U.4, Holler, E.4, Karrer, S.5, Greinix, H.6,
Elahi, F.6, Hromadnikova, I.7, Dickinson, A.M.1 1. University of New-
castle upon Tyne, Newcastle upon Tyne, United Kingdom; 2. Haukeland
Hospital, Bergen, Norway; 3. Royal Victoria Inﬁrmary, Newcastle upon
Tyne, United Kingdom; 4. Department of Haematology and Oncology,
University of Regensburg, Regensburg, Germany; 5. Department of
Dermatology, University of Regensburg, Regensburg, Germany; 6. Med-
ical University of Vienna, Vienna, Austria; 7. Charles University,
Prague, Czech Republic.
A human skin explant model has been used to predict the clinical
outcome and to study the immunopathology of human GVHD.
Whether the model gives the same predictive effect for GVHD in
different haematopoietic stem cell transplant (HSCT) settings has
not been assessed. It is also unknown whether the skin explant
result reﬂects the known biological risk factors for clinical GVHD.
In this present study the skin explant model was used to detect
graft-versus-host reactions (GVHR) in vitro for 225 eligible pa-
tient/donor pairs. Predicted skin GVHR grade was correlated with
the outcome of clinical GVHD as well as the HLAmatching status,
gender mismatches and patient age. In sibling HSCT under either
myeloablative or reduced intensity conditioning a signiﬁcant cor-
relation was observed between the predicted skin GVHR and
clinical GVHD (P  .001 and P  .033 respectively). In HSCT
using unrelated donors the involvement of T cell depletion led to
a sharp increase in false positive GVHR results and no correlation
was observed between the predicted skin GVHR and clinical
GVHD. Skin GVHR grade correlated signiﬁcantly with HLA
matching status (HLA matched sibling pairs, HLA matched unre-
lated pairs and HLA unmatched unrelated pairs). Furthermore
HLA matched sibling pairs with female to male gender mismatch
gave rise to signiﬁcantly higher overall skin GVHR grade and
higher ratio of high vs low grade skin GVHR than the sibling pairs
with all other gender combinations. Patient age was not reﬂected
in the skin explant result. In conclusion, the predictive value of the
skin explant model for aGVHD varies depending on the clinical
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